198 related articles for article (PubMed ID: 19259670)
21. The Rho-ROCK pathway as a new pathological mechanism of innate immune subversion in chronic myeloid leukaemia.
Basbous S; Levescot A; Piccirilli N; Brizard F; Guilhot F; Roy L; Bourmeyster N; Gombert JM; Herbelin A
J Pathol; 2016 Nov; 240(3):262-268. PubMed ID: 27513300
[TBL] [Abstract][Full Text] [Related]
22. Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach.
Busch C; Mulholland T; Zagnoni M; Dalby M; Berry C; Wheadon H
Cell Commun Signal; 2023 Nov; 21(1):342. PubMed ID: 38031192
[TBL] [Abstract][Full Text] [Related]
23. Differential recognition of a BCR/ABL peptide by lymphocytes from normal donors and chronic myeloid leukemia patients.
Bertazzoli C; Marchesi E; Passoni L; Barni R; Ravagnani F; Lombardo C; Corneo GM; Pioltelli P; Pogliani E; Gambacorti-Passerini C
Clin Cancer Res; 2000 May; 6(5):1931-5. PubMed ID: 10815918
[TBL] [Abstract][Full Text] [Related]
24. CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner.
Yasukawa M; Ohminami H; Kaneko S; Yakushijin Y; Nishimura Y; Inokuchi K; Miyakuni T; Nakao S; Kishi K; Kubonishi I; Dan K; Fujita S
Blood; 1998 Nov; 92(9):3355-61. PubMed ID: 9787173
[TBL] [Abstract][Full Text] [Related]
25. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia.
Yotnda P; Firat H; Garcia-Pons F; Garcia Z; Gourru G; Vernant JP; Lemonnier FA; Leblond V; Langlade-Demoyen P
J Clin Invest; 1998 May; 101(10):2290-6. PubMed ID: 9593785
[TBL] [Abstract][Full Text] [Related]
26. Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy.
Gannagé M; Abel M; Michallet AS; Delluc S; Lambert M; Giraudier S; Kratzer R; Niedermann G; Saveanu L; Guilhot F; Camoin L; Varet B; Buzyn A; Caillat-Zucman S
J Immunol; 2005 Jun; 174(12):8210-8. PubMed ID: 15944330
[TBL] [Abstract][Full Text] [Related]
27. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia.
Quintarelli C; Dotti G; De Angelis B; Hoyos V; Mims M; Luciano L; Heslop HE; Rooney CM; Pane F; Savoldo B
Blood; 2008 Sep; 112(5):1876-85. PubMed ID: 18591381
[TBL] [Abstract][Full Text] [Related]
28. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units.
Molldrem JJ; Clave E; Jiang YZ; Mavroudis D; Raptis A; Hensel N; Agarwala V; Barrett AJ
Blood; 1997 Oct; 90(7):2529-34. PubMed ID: 9326217
[TBL] [Abstract][Full Text] [Related]
29. Clonal heterogeneity of dendritic cells derived from patients with chronic myeloid leukemia and enhancement of their T-cells stimulatory activity by IFN-alpha.
Wang C; Al-Omar HM; Radvanyi L; Banerjee A; Bouman D; Squire J; Messner HA
Exp Hematol; 1999 Jul; 27(7):1176-84. PubMed ID: 10390193
[TBL] [Abstract][Full Text] [Related]
30. HLA-DR4 is associated with a diminished risk of the development of chronic myeloid leukemia (CML). Chronic Leukemia Working Party of the European Blood and Marrow Transplant Registry.
Posthuma EF; Falkenburg JH; Apperley JF; Gratwohl A; Hertenstein B; Schipper RF; Oudshoorn M; Biezen JH; Hermans J; Willemze R; Roosnek E; Niederwieser D
Leukemia; 2000 May; 14(5):859-62. PubMed ID: 10803518
[TBL] [Abstract][Full Text] [Related]
31. Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects.
Butt NM; Rojas JM; Wang L; Christmas SE; Abu-Eisha HM; Clark RE
Haematologica; 2005 Oct; 90(10):1315-23. PubMed ID: 16219567
[TBL] [Abstract][Full Text] [Related]
32. Peptide vaccines for myeloid leukaemias.
Dao T; Scheinberg DA
Best Pract Res Clin Haematol; 2008 Sep; 21(3):391-404. PubMed ID: 18790445
[TBL] [Abstract][Full Text] [Related]
33. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia.
Molldrem JJ; Lee PP; Wang C; Champlin RE; Davis MM
Cancer Res; 1999 Jun; 59(11):2675-81. PubMed ID: 10363991
[TBL] [Abstract][Full Text] [Related]
34. Correlation between preferentially expressed antigen of melanoma and tumour necrosis factor-related apoptosis-inducing ligand gene expression in different types of leukaemia patients.
Zhang W; Chi K; Zhang Y; Ma B; Shi J; Chen Y; Lei P; Li Y; Sun K
Acta Haematol; 2013; 130(4):297-304. PubMed ID: 24008770
[TBL] [Abstract][Full Text] [Related]
35. Targeted chronic myeloid leukemia therapy: seeking a cure.
Fausel C
J Manag Care Pharm; 2007 Oct; 13(8 Suppl A):8-12. PubMed ID: 17970609
[TBL] [Abstract][Full Text] [Related]
36. Identification of NM23-H2 as a tumour-associated antigen in chronic myeloid leukaemia.
Tschiedel S; Gentilini C; Lange T; Wölfel C; Wölfel T; Lennerz V; Stevanovic S; Rammensee HG; Huber C; Cross M; Niederwieser D
Leukemia; 2008 Aug; 22(8):1542-50. PubMed ID: 18496563
[TBL] [Abstract][Full Text] [Related]
37. Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy.
Yong AS; Keyvanfar K; Eniafe R; Savani BN; Rezvani K; Sloand EM; Goldman JM; Barrett AJ
Leukemia; 2008 Sep; 22(9):1721-7. PubMed ID: 18548092
[TBL] [Abstract][Full Text] [Related]
38. HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4(+) T lymphocytes.
Yasukawa M; Ohminami H; Kojima K; Hato T; Hasegawa A; Takahashi T; Hirai H; Fujita S
Blood; 2001 Sep; 98(5):1498-505. PubMed ID: 11520800
[TBL] [Abstract][Full Text] [Related]
39. Specific human cellular immunity to bcr-abl oncogene-derived peptides.
Bocchia M; Korontsvit T; Xu Q; Mackinnon S; Yang SY; Sette A; Scheinberg DA
Blood; 1996 May; 87(9):3587-92. PubMed ID: 8611681
[TBL] [Abstract][Full Text] [Related]
40. A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells.
Zorn E; Orsini E; Wu CJ; Stein B; Chillemi A; Canning C; Alyea EP; Soiffer RJ; Ritz J
Transplantation; 2001 Apr; 71(8):1131-7. PubMed ID: 11374415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]